Food Lion Pharmacy #67 Durable Medical Equipment & Medical Supplies Location: 1005 N Madison Blvd, Roxboro, North Carolina 27573 Phone: (336) 599-0851 |
Cvs Pharmacy #03531 Durable Medical Equipment & Medical Supplies Location: 900 North Madison Blvd, Roxboro, North Carolina 27573 Phone: (336) 599-8394 |
Miriam J. Lavelle-sams, O.d. P.a Medicare Supplier Location: 917 Ridge Rd, Roxboro, North Carolina 27573 Phone: (336) 599-0138 |
Walmart Pharmacy 10-1288 Durable Medical Equipment & Medical Supplies Location: 1049 Durham Rd, Roxboro, North Carolina 27573 Phone: (336) 597-5030 |
Walgreens#19008 Durable Medical Equipment & Medical Supplies Location: 304 N Madison Blvd, Roxboro, North Carolina 27573 Phone: (336) 599-0234 |
News Archive
A researcher at Moffitt Cancer Center and his international team of colleagues have reported study results on a novel multireceptor-targeted somatostatin analogue called pasireotide (SOM230) manufactured by Novartis Pharma AG.
People who received complementary therapy for curable cancers were more likely to refuse at least one component of their conventional cancer treatment, and were more likely to die as a result, according to researchers from Yale Cancer Center and the Cancer Outcomes, Public Policy and Effectiveness Research Center at Yale School of Medicine.
Not all biological weapons are created equal. They are separated into categories A through C, category A biological agents being the scariest: They are easy to spread, kill effectively and call for special actions by the pubic health system. One of these worrisome organisms is anthrax, which has already received its fair share of media attention. But work in Vince Fischetti's laboratory at Rockefeller University suggests that a newly discovered protein could be used to fight anthrax infections and even decontaminate areas in which anthrax spores have been released.
A new type of breast cancer drug developed by researchers at the University of Illinois Chicago can help halt progression of disease and is not toxic, according to phase 1 clinical trials. The drug is specifically designed for women whose cancer has stopped responding to hormone therapy.
› Verified 7 days ago